# EU MDCG 2025-10 Guidance on Post-Market Surveillance (2025)

The European Commission’s [Medical Device Coordination Group (MDCG)](https://www.pureglobal.com/glossary/eu-mdcg) issued [MDCG 2025-10: Guidance on Post-Market Surveillance (PMS)](https://health.ec.europa.eu/document/download/a9ad86b7-1b8e-4bae-beb4-48b2b3ed2f05_en?filename=mdcg_2025-10_en.pdf) on 19 December 2025. This non-binding guidance explains the MDCG’s recommended approach to the [PMS requirements](https://www.pureglobal.com/markets/european-union/mdr-and-ivdr-postmarket-surveillance) under Regulation (EU) 2017/745 (MDR) and Regulation (EU) 2017/746 (IVDR). It does not replace the Regulations or a binding interpretation of Union law.

Rather than treating PMS as a series of regulatory checkboxes, the guidance emphasizes a proactive, continuous monitoring approach that ties directly into key quality and risk processes.

## Key Components of the MDCG 2025-10 PMS Guidance

**PMS System Requirements**

MDCG 2025-10 clarifies that a PMS system must systematically and continuously collect, analyze, and act on real-world experience with a device or device group. This includes:

-   Pre-planned methods for gathering data (not just reactive sources)
    
-   Defined qualitative and quantitative analysis approaches
    
-   Integration with vigilance and risk management processes.
    

**PMS Plan Expectations**

Each device must be covered by a PMS Plan. One plan may cover a justified, clearly identified group of devices. The plan:

-   Describes methods and data sources
    
-   Defines threshold values for performance indicators
    
-   Sets out actions if trends or risks change
    
-   Is regularly updated throughout the device lifecycle
    

**PMS Reporting and Lifecycle Monitoring**

The guidance supports established regulatory outputs such as:

-   **Post-Market Surveillance Reports** (for MDR Class I and IVDR Class A and B devices)
    
-   **[Periodic Safety Update Reports (PSURs)](https://www.pureglobal.com/glossary/periodic-safety-update-report-psur)** (for the other MDR and IVDR classes)
    

These reports must feed back into the PMS cycle, driving continuous improvement and updates to technical documentation and risk files.

## Integrating PMS Into the Quality Management System

A significant focus of MDCG 2025-10 is the integration of PMS with the manufacturer’s QMS, confirming that PMS should not be isolated but embedded in existing processes:

-   **Risk Management:** PMS data must inform the [ISO 14971 risk-management process](https://www.pureglobal.com/glossary/iso-14971), including probability and severity assessments
    
-   **Clinical/Performance Evaluation:** Ongoing data must update [clinical](https://www.pureglobal.com/markets/european-union/eu-mdr-consulting/eu-mdr-clinical-evaluation-reports-cer-for-medical-devices) or [performance evaluations](https://www.pureglobal.com/markets/european-union/eu-ivdr-consulting/ivdr-per-performance-evaluation-report)
    
-   **Design & Labeling:** Insights from PMS should inform design improvements and IFU updates where needed.
    

This close linkage ensures PMS drives proactive improvements rather than delayed corrective actions.

## Why Manufacturers Should Care

MDCG 2025-10 is a practical, non-binding reference for manufacturers building MDR/IVDR post-market systems. It:

-   Expands on Articles 83 (MDR) and 78 (IVDR) for PMS interpretation
    
-   Encourages proactive data collection beyond complaint logs
    
-   Reduces regulatory risk through stronger, lifecycle-focused surveillance
    

Manufacturers should also connect reportable field action to the [FSCA definition and responsibilities](https://www.pureglobal.com/glossary/field-safety-corrective-action-fsca). Adapting PMS processes early can enhance safety, reduce non-conformance findings, and support smoother audits and regulatory reviews.

## Immediate Compliance Actions

Manufacturers and QMS leads should:

-   Review current PMS systems against MDCG 2025-10 expectations
    
-   Update PMS Plans to include proactive data sources
    
-   Ensure linkage between PMS, risk management, and clinical/performance evaluation
    
-   Document thresholds and decision criteria for risk changes
    

These actions help align PMS processes with MDR/IVDR requirements and current MDCG best practice.

## External Links

-   📄 [**Official MDCG 2025-10 guidance PDF** (EU Health site)](https://health.ec.europa.eu/document/download/a9ad86b7-1b8e-4bae-beb4-48b2b3ed2f05_en?filename=mdcg_2025-10_en.pdf)
    
-   🌐 [**MDCG 2025-10 news announcement** (EU Health)](https://health.ec.europa.eu/latest-updates/mdcg-2025-10-guidance-post-market-surveillance-medical-devices-and-vitro-diagnostic-medical-devices-2025-12-19_en)

[Canonical page](https://www.pureglobal.com/news/eu-mdcg-2025-10-guidance-on-post-market-surveillance-2025)
